This Next-Gen Obesity Drug: Can It Save Novo Nordisk?
Novo Nordisk faces intense pressure in the fast-growing obesity treatment space. This article dives into whether this...
Biotech
Biotech insights await. This page curates 5 articles on Tempus, Moderna, Praxis, ImmunityBio and market moves to help you evaluate stocks and sharpen your portfolio strategy.
58 articlesMediWound (MDWD) 2025 Earnings: A Comprehensive Look
As 2025 unfolds, MediWound faces a pivotal year for debt, cash, and milestones. This analysis breaks down what mediwo...
Biotech Giants 2026: Top Stocks to Buy for Growth and Safety
Biotech giants 2026 could offer a compelling mix of growth and stability for investors. This article dives into two p...
Pulmonx (Lung) 2025 Earnings Outlook for Investors
Pulmonx is navigating a pivotal year as it advances its lung care devices while contending with pacing competition an...
Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Sophia Genetics (SOPH) 2025 Investing Outlook for Investors
In 2025, Sophia Genetics is at a crossroads between expanding its software platform and tightening its financial disc...
Investment Firm Adds Nearly $4 Million in DYN Shares
A major investment firm boosted its Dyne Therapeutics stake by nearly $4 million, highlighting renewed interest in DY...
Xeris Biopharma (XERS) 2025 Outlook: Earnings & Pipeline
A thoughtful look at Xeris Biopharma's Q4 2025 earnings, the company’s pipeline milestones, and what xeris biopharma ...
Disc Medicine Sells $720k: CFO Moves After FDA Rejection
A biotech insider trade draws attention after an FDA setback. This article unpacks the CFO's $720k stock sale at Disc...
Immortal Life Henrietta Lacks Settlement Moves Forward
A confidential settlement in Maryland ends a high-profile dispute over HeLa cell patents and profits, signaling a new...
Down Over Past Year: Can Hims & Hers Stock Rebound?
Hims & Hers Health shares have been hammered, marked by a steep decline over past year. This article breaks down the ...